Friday, November 08, 2019 1:16:33 PM
New York Yankees and Duke Basketball
Recent RAPT News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:15:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 01:08:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:03:10 PM
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:29:38 PM
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:52:45 PM
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations • GlobeNewswire Inc. • 02/13/2024 01:00:00 PM
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:08:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:08 PM
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 04:03:08 PM
- RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November • GlobeNewswire Inc. • 11/01/2023 08:05:00 PM
- RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September • GlobeNewswire Inc. • 08/30/2023 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/18/2023 04:15:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:02:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/11/2023 12:57:09 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM